PPARA and metabolic syndrome: Shulman and Mangelsdorf[7] recently reviewedliterature demonstrating that the metabolic syndrome could betreated by altering the activity of NR heterodimers containingRXR and partners PPAR, LXR, FXR, and TR by using ligands specificfor PPAR, LXR, FXR, and TR.